Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset below-consensus EPS outlook.

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

The tragic early death of "Friends" star Matthew Perry from a ketamine overdose in 2023 has swung a spotlight on th ...

The anesthetic ketamine is being hailed as a breakthrough therapy for people with post-traumatic stress disorder (PTSD), treatment-resistant depression and other mood disorders.

A federal judge on Tuesday ordered government agencies to restore public access to health-related webpages and datasets that ...

The American Society of Anesthesiologists has issued new guidance on ketamine administration for patients suffering from post-traumatic stress disorder, treatment-resistant depression and other mood ...

U.S. District Judge John D. Bates granted a restraining order temporarily reversing the Trump administration’s moves to ...

A federal judge today, February 11, gave the Trump administration until 11:59 pm tonight to restore public documents and datasets that were abruptly removed or altered from federal health websites to ...

Gottlieb, who led the agency during the first Trump presidency, supports a reversion to an earlier interpretation of the 21st Century Cures Act.

While a pause on federal health agencies is nothing new during presidential transitions, the Trump Administration’s ...

Incyte has a strong track record of revenue growth and a robust pipeline, targeting over 10 high-impact product launches by ...